恩华药业(002262) - 2021 Q1 - 季度财报

Financial Performance - The company's revenue for Q1 2021 was CNY 904,072,358.63, representing a 22.58% increase compared to CNY 737,516,446.16 in the same period last year[3]. - Net profit attributable to shareholders was CNY 167,792,106.86, up 21.68% from CNY 137,901,538.79 year-on-year[3]. - The net profit after deducting non-recurring gains and losses was CNY 168,364,993.50, reflecting a 21.04% increase from CNY 139,097,384.74 in the previous year[3]. - Basic earnings per share increased to CNY 0.17, up 21.43% from CNY 0.14 in the previous year[3]. - The company forecasts a net profit attributable to shareholders of approximately 388.10 million yuan for the first half of 2021, representing a growth of 10.00% compared to the same period last year[16]. - The company reported a net profit of CNY 2,921,054,636.22, up from CNY 2,753,262,529.36, indicating a growth of approximately 6.1% in retained earnings[25]. - The net profit for Q1 2021 was CNY 198,039,196.86, an increase of 21.6% compared to CNY 162,762,755.89 in the same period last year[33]. - The company reported a profit before tax of CNY 192,008,244.63, an increase of 21.4% from CNY 158,077,005.70 in Q1 2020[30]. Cash Flow and Investments - The net cash flow from operating activities was CNY 259,099,727.39, which is a 9.27% increase compared to CNY 237,109,709.40 in the same period last year[3]. - Cash received from other operating activities decreased by 33.75% year-on-year, influenced by the reclassification of interest income from structured deposits[11]. - The net cash flow from investment activities decreased by 5201.78% year-on-year, due to the combined effects of cash flows related to structured deposits[11]. - The company incurred a net cash outflow from investing activities of CNY -327,499,878.80, compared to CNY -6,177,167.64 in the previous year[36]. - The company’s cash flow from financing activities resulted in a net outflow of CNY -6,861,853.33, compared to CNY -1,312,830.85 in the same period last year[37]. - The net cash flow from investment activities was -298,871,694.01 CNY, compared to -23,726,136.35 CNY in the previous period[39]. Assets and Liabilities - Total assets at the end of the reporting period were CNY 5,014,948,630.20, a 5.61% increase from CNY 4,748,440,264.63 at the end of the previous year[3]. - Total liabilities reached CNY 741,933,380.60, up from CNY 642,942,712.16, marking an increase of around 15.4%[24]. - Current liabilities rose to CNY 634,125,584.86, compared to CNY 574,945,454.48, indicating an increase of approximately 10.3%[24]. - The total non-current liabilities increased by 58.55% compared to the beginning of the period, primarily due to the increase in lease liabilities[10]. - The total assets increased to CNY 5,014,948,630.20, up from CNY 4,748,440,264.63, representing a growth of approximately 5.6% year-over-year[25]. - The total liabilities rose from 642,942,712.16 CNY to 679,365,577.17 CNY, with an increase of 36,422,865.01 CNY due to the new leasing standard[42]. Shareholder Information - The total number of ordinary shareholders at the end of the reporting period was 50,101, with the largest shareholder, Xuzhou Enhua Investment Co., Ltd., holding 34.74%[6]. - The actual controllers of the company hold a combined 51.07% of the shares, ensuring significant control over the company[7]. - Net assets attributable to shareholders reached CNY 4,292,081,108.82, which is a 4.10% increase from CNY 4,123,001,148.33 at the end of the previous year[3]. - The company's equity attributable to shareholders rose to CNY 4,292,081,108.82 from CNY 4,123,001,148.33, reflecting an increase of about 4.1%[25]. Expenses - R&D expenses increased by 86.69% year-on-year, reflecting the company's increased investment in research and development[10]. - Management expenses increased by 33.60% year-on-year, mainly due to increases in wages, depreciation, and utility costs[10]. - Total operating costs amounted to CNY 704,655,966.73, up 22.3% from CNY 575,804,943.90 year-over-year[29]. - The company's sales expenses increased to CNY 388,289,983.65, up 17.9% from CNY 329,171,039.88 in the previous year[29]. - Research and development expenses increased significantly to CNY 67,570,448.87, up 86.7% from CNY 36,193,275.93 in the previous year[29]. Inventory and Receivables - The company’s inventory rose to CNY 342,432,958.03 from CNY 299,767,499.41, representing an increase of approximately 14.2%[26]. - Accounts receivable increased to CNY 749,527,393.75 from CNY 725,153,290.02, showing a growth of approximately 3.4%[26]. - Other receivables increased by 160.16% compared to the beginning of the period, primarily due to the increase in business personnel's petty cash[10]. Financial Adjustments and Standards - The company adopted the new leasing standard starting January 1, 2021, leading to adjustments in the financial statements[40]. - The first quarter report was not audited, indicating preliminary financial data[46].